termsTerm
Biochemical recurrence (BCR)
PSA rising again after surgery or radiation, usually years before anything shows on a scan.
PSA ≥0.2 ng/mL after prostatectomy or nadir +2 after radiation. PSMA PET detects disease at PSA <0.5 in most men, enabling salvage radiation or metastasis-directed therapy. EMBARK (2023) showed enzalutamide ± ADT delays metastasis in high-risk BCR (PSA doubling time ≤9 months).
Clinical: what this kind of term is about · animated schematic, not to scale
Category
Clinical
Pages like this
not linked directly; found by shared links- CompanyBlue Earth Diagnostics (Bracco)
Shares Fluciclovine F-18, Prostate cancer.
- TermPSA50 / PSA90 response
- CollectionProstate Cancer Foundation (PCF)
Shares PSA (prostate-specific antigen), PSMA PET, Prostate cancer.
- IdeaA test to tell true oligometastatic disease from hidden widespread spread
Shares PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer, Prostate cancer.
- CompanyClarity Pharmaceuticals
Shares PSMA PET, Prostate cancer.
- PersonJeremie Calais
Shares PSMA PET, Prostate cancer.
- ProductFlotufolastat F-18
Shares PSMA PET, Prostate cancer.
- TrialproPSMA
Shares PSMA PET, Prostate cancer.